Skip to content

Released Mar 11, 2021, after the close

10-K filed Mar 11, 2021, 70 days after period end · 0001564590-21-012514

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derived−100.0% vs Q4 2019−100.0% vs Q3 2020
Net Income-$18.60MderivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$18,796,000N/M
Operating Cash Flowderived-$16,383,000N/M
Free Cash Flowderived-$16,395,000N/M

What the release said

The release

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019Q4 2018Q4 2017
Revenue$0.00$696.00K$1.69M$993.00K
Net Income-$18.60M-$24.99M-$10.60M-$13.86M
EPS Diluted—-$1.31-$0.60-$1.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR